NCT00002180已完成1 期
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, and Pharmacokinetics, and Antiviral Activity of 9-[(R)-2-(Phosphonomethoxy)Propyl] Adenine (PMPA) in HIV-Infected Patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 4
研究概览
简要总结
The purpose of this study is to see if it is safe and effective to give PMPA to HIV-infected patients. This study also examines how the body handles PMPA.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Laboratory diagnosis of HIV infection.
- •CD4 cell count >= 200 cells/mm3 within 28 days prior to entry.
- •Plasma HIV RNA >= 10,000 copies/ml within 28 days of entry.
- •Minimum life expectancy of 12 months.
排除标准
- •Co-existing Condition:
- •Patients with any of the following symptoms or conditions are excluded:
- •Active, serious infections (other than HIV) that require parental antibiotic therapy. Patients may be considered recovered if at least 2 weeks have elapsed following cessation of parental therapy before enrollment.
- •Active clinically significant medical problems that include cardiac disease (e.g., symptoms of ischemia, congestive heart failure, or arrhythmia).
- •Positive test for Hepatitis B surface antigen or Hepatitis C antibody in serum.
- •Patients with any of the following prior conditions are excluded:
- •History of malignancy other than basal cell carcinoma or cutaneous Kaposi's sarcoma.
- •Patients who are receiving:
- •Antiretroviral therapy, including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents.
- •Interferon or interleukin therapy, aminoglycoside antibiotics, amphotericin B, cidofovir, diuretics, foscarnet, ganciclovir, itraconazole, fluconazole, ketoconazole (topical allowed), isoniazid, rifampin, rifabutin, clarithromycin, azithromycin, systemic chemotherapeutic agents, systemic corticosteroids, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (probenecid) and other investigational agents.
- •Within 2 weeks prior to entry:
- •Antiretroviral therapy, including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents.
- •Interferon or interleukin therapy, aminoglycoside antibiotics, amphotericin B, cidofovir, diuretics, foscarnet, ganciclovir, itraconazole, fluconazole, ketoconazole (topical allowed), isoniazid, rifampin, rifabutin, clarithromycin, azithromycin, systemic chemotherapeutic agents, systemic corticosteroids, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (probenecid) and other investigational agents.
- •Active drug or alcohol abuse as demonstrated by a positive screening test for drugs of abuse (except marijuana or drugs used for medical indications), or substance abuse considered sufficient to hinder patient compliance.
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected PatientsHIV InfectionsNCT00002415Gilead Sciences175
已完成
不适用
A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive PatientsHIV InfectionsNCT00002426Gilead Sciences390
已完成
2 期
The Effects of Prednisone on HIV Levels and the Immune SystemHIV InfectionsNCT00000921National Institute of Allergy and Infectious Diseases (NIAID)118
已完成
2 期
A Study of Viracept in AIDS Patients With Cytomegalovirus RetinitisCytomegalovirus RetinitisHIV InfectionsNCT00002169Agouron Pharmaceuticals
已完成
1 期
Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA GelHIV InfectionsNCT00028132National Institute of Allergy and Infectious Diseases (NIAID)120